IL17A and neoplasm: The release of IL-1β by DCs in response to doxorubicin treatment plays an important role in recruiting IL-17 producing γδ T-cells which subsequently recruit anti-tumoral IFN-γ expressing αβ CD8+ T-cells into the tumor microenvironment (41).